SG11201705361PA - Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease - Google Patents

Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Info

Publication number
SG11201705361PA
SG11201705361PA SG11201705361PA SG11201705361PA SG11201705361PA SG 11201705361P A SG11201705361P A SG 11201705361PA SG 11201705361P A SG11201705361P A SG 11201705361PA SG 11201705361P A SG11201705361P A SG 11201705361PA SG 11201705361P A SG11201705361P A SG 11201705361PA
Authority
SG
Singapore
Prior art keywords
treatment
combination therapy
liver disease
fatty liver
alcoholic fatty
Prior art date
Application number
SG11201705361PA
Inventor
Geraldine C Harriman
Rosana Kapeller-Libermann
William F Westlin
H James Harwood
Original Assignee
Gilead Apollo Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Apollo Llc filed Critical Gilead Apollo Llc
Publication of SG11201705361PA publication Critical patent/SG11201705361PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11201705361PA 2015-01-09 2016-01-08 Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease SG11201705361PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101726P 2015-01-09 2015-01-09
PCT/US2016/012673 WO2016112305A1 (en) 2015-01-09 2016-01-08 Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
SG11201705361PA true SG11201705361PA (en) 2017-08-30

Family

ID=56356482

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705361PA SG11201705361PA (en) 2015-01-09 2016-01-08 Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Country Status (13)

Country Link
US (2) US20180021341A1 (en)
EP (2) EP3242722A4 (en)
JP (2) JP2018501276A (en)
KR (1) KR20170102299A (en)
CN (1) CN107106873A (en)
AU (1) AU2016205138A1 (en)
BR (1) BR112017014341A2 (en)
CA (1) CA2972919A1 (en)
EA (2) EA201892625A1 (en)
HK (2) HK1243369A1 (en)
MX (1) MX2017008844A (en)
SG (1) SG11201705361PA (en)
WO (1) WO2016112305A1 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
TWI491606B (en) 2009-07-13 2015-07-11 Gilead Sciences Inc Apoptosis signal-regulating kinase inhibitors
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
AU2015267148B2 (en) 2014-05-28 2021-07-29 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
EP3207123A1 (en) 2014-10-17 2017-08-23 Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
PT3191470T (en) 2015-07-06 2019-06-05 Gilead Sciences Inc Cot modulators and methods of use thereof
EA201890913A1 (en) * 2015-11-25 2018-11-30 Джилид Аполло, Ллс PYRAZOL COMPOUNDS AS ACC INHIBITORS AND THEIR APPLICATION
EA201890949A1 (en) 2015-11-25 2018-12-28 Джилид Аполло, Ллс ESSENTIAL ETHERIC ACETYL-COA-CARBOXYLASE INHIBITORS AND THEIR OPTIONS
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment for modulating gut microbiota
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
CN109415685B (en) 2016-05-05 2023-07-04 儿童医院医疗中心 Methods for in vitro manufacturing of fundus tissue and compositions related thereto
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
EP3468962A1 (en) 2016-06-13 2019-04-17 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
NZ753051A (en) 2016-11-04 2023-03-31 Children’S Hospital Medical Center Liver organoid compositions and methods of making and using same
CN110062634A (en) * 2016-11-10 2019-07-26 盖尔梅德研究与发展有限公司 The inhibition of fibrosis in patients with nonalcoholic fatty liver disease
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CN110191724A (en) * 2016-11-10 2019-08-30 盖尔梅德研究与发展有限公司 The treatment of fibrosis
SG10202105768WA (en) 2016-12-05 2021-06-29 Childrens Hospital Med Ct Colonic organoids and methods of making and using same
CA3049926A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3571205B1 (en) * 2017-01-22 2023-08-30 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
US11142531B2 (en) 2017-03-24 2021-10-12 Zhejiang Hisun Pharmaceutical Co., Ltd. Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof
SI3600309T1 (en) 2017-03-28 2022-10-28 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
CN110475556A (en) * 2017-03-28 2019-11-19 吉利德科学公司 The method for treating liver disease
AU2018250614A1 (en) * 2017-04-12 2019-10-17 Gilead Sciences, Inc. Methods of treating liver disease
WO2018193007A1 (en) * 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
EP3609523B1 (en) * 2017-04-24 2022-03-02 Tsinghua University Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
JP2020524181A (en) * 2017-06-19 2020-08-13 アリーナ ファーマシューティカルズ， インコーポレイテッド Compounds and methods for the treatment of NAFLD and NASH
EP3655409B1 (en) * 2017-07-17 2023-12-27 Nanjing Ruijie Pharmatech Co., Ltd. Novel compounds and their uses as acc inhibitors
WO2019020041A1 (en) * 2017-07-26 2019-01-31 南京圣和药业股份有限公司 Compound as acc inhibitor and use thereof
CN109316601B (en) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 Pharmaceutical composition and use thereof
EP3676262A4 (en) 2017-09-03 2021-03-31 Angion Biomedica Corp. Vinylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors
US11033601B2 (en) * 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
TWI814744B (en) * 2017-10-06 2023-09-11 美商基利科學股份有限公司 Combination therapy comprising an acc inhibitor
WO2019085772A1 (en) * 2017-11-06 2019-05-09 深圳市图微安创科技开发有限公司 Treatment of biliary cirrhosis based on oxyntomodulin analogue glp-1r/gcgr dual-target agonist peptide
CN107693514A (en) * 2017-12-04 2018-02-16 威海贯标信息科技有限公司 A kind of glug arranges net composition
MA51889A (en) 2018-01-31 2021-05-05 Heparegenix Gmbh KINASE MKK4 PROTEIN INHIBITORS TO PROMOTE HEPATIC REGENERATION OR TO REDUCE OR PREVENT HEPATOCYTE DEATH
US20210113561A1 (en) * 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2019209738A1 (en) * 2018-04-24 2019-10-31 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
EP3810139A1 (en) 2018-06-21 2021-04-28 HepaRegeniX GmbH Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2020016243A1 (en) 2018-07-16 2020-01-23 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2020037023A1 (en) * 2018-08-14 2020-02-20 Avolynt Method for treating primary sclerosing cholangitis
MX2021002428A (en) 2018-08-31 2023-01-02 Pfizer Combinations for treatment of nash/nafld and related diseases.
US20210338826A1 (en) * 2018-09-06 2021-11-04 Galmed Research And Development Ltd Combination therapy for the treatment of liver disease
CN110950884B (en) * 2018-09-27 2024-03-26 上海翰森生物医药科技有限公司 Di-ring derivative-containing inhibitor, preparation method and application thereof
AU2019385438A1 (en) * 2018-11-20 2021-05-27 The National Institutes of Pharmaceutical R&D Co., Ltd. Spiro compound and medical uses thereof
KR20210114457A (en) 2019-01-15 2021-09-23 길리애드 사이언시즈, 인코포레이티드 FXR (NR1H4) modulating compound
KR20210129128A (en) 2019-02-19 2021-10-27 길리애드 사이언시즈, 인코포레이티드 Solid Forms of FXR Agonists
AU2020267576A1 (en) 2019-05-08 2021-12-09 Aligos Therapeutics, Inc. Modulators of THR-β and methods of use thereof
TWI770527B (en) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot modulators and methods of use thereof
JP7374233B2 (en) * 2019-07-02 2023-11-06 ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 Thienopyrimidine derivatives with stereoconfiguration and their applications in drugs
US20220340561A1 (en) 2019-07-29 2022-10-27 Heparegenix Gmbh Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AR119594A1 (en) 2019-08-09 2021-12-29 Gilead Sciences Inc THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF
CN110628810B (en) * 2019-08-13 2022-06-28 浙江大学 Method for improving photosynthetic efficiency of plant
WO2021040440A1 (en) * 2019-08-30 2021-03-04 (주)셀트리온 Pharmaceutical composition for treating or preventing nonalcoholic steatohepatitis (nash)
WO2021133948A1 (en) 2019-12-23 2021-07-01 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
CA3164361A1 (en) 2020-01-15 2021-07-22 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
JP2021134211A (en) 2020-02-24 2021-09-13 ファイザー・インク Combinations for treating nafld/nash and related diseases
JP2022058085A (en) 2020-02-24 2022-04-11 ファイザー・インク Combination of inhibitors of diacylglycerol acyltransferase 2 and inhibitors of acetyl-coa carboxylase
WO2021182876A1 (en) * 2020-03-11 2021-09-16 동아에스티 주식회사 Pharmaceutical composition for prevention or treatment of nonalcoholic steatohepatitis
US11655237B2 (en) 2020-03-30 2023-05-23 Gilead Sciences, Inc. Solid forms of a Cot inhibitor compound
US11845737B2 (en) 2020-04-02 2023-12-19 Gilead Sciences, Inc. Process for preparing a Cot inhibitor compound
CN111407892A (en) * 2020-04-08 2020-07-14 中国药科大学 ACS L4 and application thereof in NASH
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CA3182134A1 (en) 2020-05-21 2021-11-25 Shionogi & Co., Ltd. Pharmaceutical composition for treating fatty liver disease
EP4000616A1 (en) 2020-11-17 2022-05-25 Inventiva Combination therapy for the treatment of a liver disease
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
CA3214961A1 (en) 2021-03-29 2022-10-06 Gilead Sciences, Inc. Khk inhibitors
TW202345826A (en) 2021-06-04 2023-12-01 美商基利科學股份有限公司 Methods of treating nash
TW202311256A (en) 2021-06-18 2023-03-16 美商基利科學股份有限公司 Il-31 modulators for treating fxr-induced pruritis
WO2023034381A1 (en) * 2021-08-31 2023-03-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Quantitative systems pharmacology methods for identifying therapeutics for disease states
WO2023047203A1 (en) * 2021-09-25 2023-03-30 Torrent Pharmaceuticals Ltd Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155611A1 (en) * 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
US20100113473A1 (en) * 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
WO2012090219A2 (en) * 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
EA030264B1 (en) * 2011-11-11 2018-07-31 Джилид Аполло, Ллс Acc inhibitors and uses thereof
JP6417402B2 (en) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー ACC inhibitors and uses thereof
CN105358152A (en) * 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc inhibitors and uses thereof
EA030942B1 (en) 2013-05-10 2018-10-31 Джилид Аполло, Ллс Acc inhibitors and uses thereof
CA2911822A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2018501276A (en) 2018-01-18
JP2020109130A (en) 2020-07-16
HK1246232A1 (en) 2018-09-07
MX2017008844A (en) 2018-03-14
EP3242722A4 (en) 2018-07-11
CA2972919A1 (en) 2016-07-14
AU2016205138A1 (en) 2017-07-13
BR112017014341A2 (en) 2018-03-27
US20180021341A1 (en) 2018-01-25
EP3242722A1 (en) 2017-11-15
EP3597271A1 (en) 2020-01-22
HK1243369A1 (en) 2018-07-13
EA201892625A1 (en) 2019-07-31
WO2016112305A1 (en) 2016-07-14
CN107106873A (en) 2017-08-29
KR20170102299A (en) 2017-09-08
EA201791258A1 (en) 2017-12-29
US20190381045A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
HK1246232A1 (en) Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
IL253945A0 (en) Kdm1a inhibitors for the treatment of disease
HK1247922A1 (en) Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
HK1247202A1 (en) Compounds for the treatment of cancer
HK1259458A1 (en) Gemcabene combinations for the treatment of cardiovascular disease
ZA201607740B (en) Treatment of the complications of chronic liver disease with caspase inhibitors
IL254266A0 (en) Glucosylceramide synthase inhibitors for the treatment of diseases
EP3132795A4 (en) Composition for preventing or treating fatty liver diseases
SG11202102684VA (en) Treatment for non-alcoholic fatty liver disease
EP3362053A4 (en) Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
ZA201805080B (en) Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease
GB201506654D0 (en) Formulations for inhibition of PCSK9 for the treatment of hypercholesterolemia
PL3302523T3 (en) Composition for the treatment of tissue lesions
PL3484475T3 (en) 1-methylnicotinamide for the treatment of cardiovascular disease
PL3233074T3 (en) Treatment for non-alcoholic fatty liver diseases
GB201411467D0 (en) 7-hydroxy cannabidiol (7-oh-cbd) for use in the treatment of non-alcoholic fatty liver disease (nafld)
ZA201706986B (en) Compositions for the treatment of kidney and/or liver disease
IL257689B (en) Pharmaceutical compositions and methods for the treatment of hypoxia-related diseases
GB201622116D0 (en) Treatment of liver disease
PT3340975T (en) Formulation for the treatment of acne
HRP20181460T1 (en) 4-oxo-n-(4-hydroxyphenyl)retinamide derivatives as therapeutic agents for the treatment of cancer
PL3273997T3 (en) Compositions for the treatment of cold
GB201509781D0 (en) Non-alcoholic fatty liver disease